Paliperidone extended release
Yang LP, Plosker GL.
Wolters Kluwer Health
Adis, Auckland, New Zealand.
CNS Drugs. 2007;21(5):417-25; discussion 426-7.


Paliperidone extended release (ER) is an atypical antipsychotic that is administered orally once daily to provide consistent plasma drug concentrations over 24 hours in adult patients with schizophrenia. In four well controlled trials, once-daily administration of paliperidone ER 3-12 mg over 6 weeks was more effective than placebo in reducing the positive and negative symptoms experienced by adult patients with schizophrenia, including elderly individuals aged > or =65 years. Patients with schizophrenia treated with paliperidone ER achieved greater improvement in clinically relevant measures of personal and social functioning and disease severity than those who received placebo. In another well controlled trial, paliperidone ER demonstrated superior efficacy to placebo in preventing the recurrence of schizophrenia symptoms. In patients who experienced a recurrence, time to recurrence was delayed with paliperidone ER compared with placebo triangle Paliperidone ER 3-12 mg/day for 6 weeks was generally well tolerated by patients with schizophrenia in clinical trials.
NMDA antagonists
New antipsychotics
Psychotic depression
Atypical antipsychotics
Bipolars v schizophrenics
Schizophrenia: new drugs
Amisuplride for depression
Anhedonia and schizophrenia
Anhedonia and schizophrenia
Serotonin model of schizophrenia
Dopamine model of schizophrenia
Amisulpride for negative symptoms
Atypical antipsychotics for schizophrenia

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family